What is Biorep Technologies?
Founded in 1994, Biorep Technologies operates as a specialized, full-service development firm with a primary focus on the medical device industry. With over 25 years of technical expertise, the company maintains ISO 13485 certification and FDA registration, ensuring rigorous compliance and quality standards. By bridging the gap between research-driven innovation and commercial-grade manufacturing, Biorep serves as a critical partner for institutions seeking to translate biological research into tangible medical solutions. Their market position is defined by a unique blend of family-owned stability and high-tech engineering capabilities, specifically tailored to support the pursuit of a biological cure for type I diabetes.
How much funding has Biorep Technologies raised?
Biorep Technologies has raised a total of $630K across 2 funding rounds:
Debt
$350K
Debt
$280K
Debt (2020): $350K with participation from PPP
Debt (2021): $280K led by PPP
Key Investors in Biorep Technologies
PPP
Public-Private Partnership
What's next for Biorep Technologies?
With the recent capital injection, Biorep Technologies is well-positioned to scale its manufacturing infrastructure and accelerate the development of its proprietary medical device pipeline. The strategic allocation of these funds will likely focus on enhancing R&D capabilities and expanding the firm's footprint in the clinical research support market. As the company transitions into this next phase of growth, the focus remains on maintaining its high standards of regulatory compliance while scaling operations to meet the increasing demand for specialized medical hardware. This investment serves as a catalyst for long-term operational efficiency and technological advancement in the diabetes research space.
See full Biorep Technologies company page
